Intelligence / Healthtech / New Clinical Trials / Boehringer Ingelheim
Clinicaltrial registered9 Nov 2026
Boehringer Ingelheim
9 Nov 2026: Trial registered · Real-world Outcome of Zongertinib in Japan (J-HERZ). Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 9 Nov 2026
- Title
- Real-world Outcome of Zongertinib in Japan (J-HERZ)
- Conditions
- Non-small Cell Lung Cancer
- Study Type
- Observational
- Status
- Not Yet Recruiting
- Countries
- Japan
- Country
- Japan
- Reference
- NCT07926308
- Location
- Japan
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Boehringer Ingelheim
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Boehringer Ingelheim in our registers.
16 NovBoehringer Ingelheimtrial registered · HealthtechClinical10 NovBoehringer Ingelheimtrial registered · HealthtechClinical9 NovBoehringer Ingelheimtrial registered · HealthtechClinical9 NovBoehringer Ingelheimtrial registered · HealthtechClinical4 NovBoehringer Ingelheimtrial registered · HealthtechClinical30 OctBoehringer Ingelheimtrial registered · HealthtechClinical30 OctBoehringer Ingelheimtrial registered · HealthtechClinical
More from Japan
New Clinical Trials
17 NovNS Pharma, Inc.trial registered · A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular DystrophyClinical12 NovNovo Nordisk A/Strial registered · A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothClinical12 NovNovo Nordisk A/Strial registered · A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseClinical12 NovNovo Nordisk A/Strial registered · A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or BothClinical10 NovBoehringer Ingelheimtrial registered · A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With ObrixtamigClinical10 NovEli Lilly and Companytrial registered · A Study of LY4336619 in Adult Participants With Advanced Solid TumorsClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.